← Every company
Enanta Pharmaceuticals Inc Patents
What Enanta Pharmaceuticals Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
ENTA on carbonthat →Filings on file
55
Granted
5
Still pending
50
Filed under
3 names
55 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| ANTI-INFLAMMATORY COMPOUNDSFiled as ENANTA PHARMACEUTICALS, INC.2026-03-20JONATHAN THIELMAN | pending |
| ANTI-INFLAMMATORY COMPOUNDSFiled as ENANTA PHARMACEUTICALS, INC.2026-03-11SEAN RAFFERTY | pending |
| ANTI-INFLAMMATORY COMPOUNDSFiled as ENANTA PHARMACEUTICALS, INC.2026-03-11SAMUEL BARTLETT | pending |
| ANTI-INFLAMMATORY COMPOUNDSFiled as ENANTA PHARMACEUTICALS, INC.2026-02-25ROBERT LEON | pending |
| ANTI-INFLAMMATORY COMPOUNDSFiled as ENANTA PHARMACEUTICALS, INC.2026-02-25SOURAV GHORAI | pending |
| PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORSFiled as ENANTA PHARMACEUTICALS, INC.2026-02-06JIAJUN ZHANG | pending |
| Pharmaceutical Compounds And Compositions As C-Kit Kinase InhibitorsA61P 35/00, C07D 413/14, A61K 31/422, A61K 31/4245, A61K 31/437, A61K 31/4439, A61K 31/444, A61K 31/496, A61K 31/5377, C07D 401/12, C07D 401/14, C07D 403/12, C07D 403/14, C07D 405/14, C07D 471/04, C07D 487/04, C07D 498/04, C07D 519/00Filed as Enanta Pharmaceuticals, Inc.2026-02-06Jiajun ZHANG | pending |
| ANTI-INFLAMMATORY COMPOUNDSFiled as ENANTA PHARMACEUTICALS, INC.2025-12-16SOURAV GHORAI | pending |
| Anti-Inflammatory CompoundsC07D 498/04, A61K 31/404, A61K 31/4178, A61K 31/4184, A61K 31/4196, A61K 31/437, A61K 31/444, A61K 31/4545, A61K 31/4985, A61K 31/501, A61K 31/513, A61K 31/5383, C07D 403/10, C07D 405/14, C07D 471/04, C07D 487/04, C07D 519/00Filed as Enanta Pharmaceuticals, Inc.2025-12-16Sourav GHORAI | pending |
| Spiropyrrolidine Derived Antiviral AgentsA61P 11/00, C07D 487/10, A61P 31/14, A61K 9/0019, A61K 9/0073Filed as Enanta Pharmaceuticals, Inc.2025-11-21Ruichao SHEN | pending |
| Anti-Inflammatory CompoundsFiled as Enanta Pharmaceuticals Inc.2025-09-23Sourav GHORAI | pending |
| Anti-Inflammatory CompoundsFiled as Enanta Pharmaceuticals, Inc.2025-08-05Sean RAFFERTY | pending |
| 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use ThereofA61P 1/00, C07C 311/21, C07D 265/36, C07D 277/36, C07C2601/08, C07C2602/10, C07C2601/16, C07C2601/14, A61P 1/16, A61P 3/00, A61P 9/00, A61P 13/12, A61K 31/426, C07C 307/10, C07C 311/29, C07D 209/08, C07D 209/18, C07D 209/30, C07D 209/44, C07D 211/96, C07D 213/71, C07D 215/58, C07D 217/08, C07D 217/20, C07D 231/12, C07D 231/18, C07D 263/46, C07D 277/22, C07D 277/54, C07D 295/26, C07D 307/79, C07D 307/81, C07D 307/82, C07D 317/72, C07D 333/34, C07D 333/62, C07D 401/04, C07D 413/10, C07D 417/04, C07D 417/06, C07D 417/10, C07D 417/12, C07D 417/14, C07D 471/04, C07D 487/04, C07D 513/04Filed as Enanta Pharmaceuticals, Inc.2025-06-18Guoqiang WANG | pending |
| Antiviral Heterocyclic CompoundsC07D 491/048, C07D 519/00, A61P 31/14, A61P 31/16, A61K 31/4355, A61K 31/4709, A61K 45/06, C07B2200/05Filed as Enanta Pharmaceuticals, Inc.2025-06-09Adam SZYMANIAK | pending |
| Pharmaceutical Compounds And Compositions As Modulators Of MAS-Related G-Protein Receptor X2C07D 401/14, C07D 491/107, A61K 31/416, A61K 31/4535, A61K 31/454, A61K 31/4545, A61K 31/4709, A61K 31/4725, A61K 31/497, C07D 211/56, C07D 401/04, C07D 401/12, C07D 405/12, C07D 405/14, C07D 409/12, C07D 409/14, C07D 413/14, C07D 417/14, C07D 471/04Filed as Enanta Pharmaceuticals, Inc.2025-04-08Xuri GAO | pending |
| PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2Filed as ENANTA PHARMACEUTICALS, INC.2025-04-08XURI GAO | pending |
| Benzodiazepine Derivatives as RSV InhibitorsA61K 31/5513, C07D 243/16, C07D 413/12, C07D 513/04, A61P 31/12, A61P 11/00, A61P 31/16, A61K 31/56, A61K 31/58, A61K 45/06, A61K2300/00, C07D 243/24, C07D 413/14, C07D 417/12, C07D 417/14, C07D 471/04, C07D 471/08, C07D 487/04, C07D 491/048, C07D 495/04, C07D 498/08Filed as Enanta Pharmaceuticals, Inc.2025-04-03Brian C. SHOOK | pending |
| Anti-Inflammatory CompoundsFiled as Enanta Pharmaceuticals, Inc.2025-03-21Jonathan THIELMAN | pending |
| ANTI-INFLAMMATORY COMPOUNDSFiled as Enanta Pharmaceuticals, Inc.2025-03-13Sean RAFFERTY | pending |
| ANTI-INFLAMMATORY COMPOUNDSFiled as Enanta Pharmaceuticals, Inc.2025-03-13Samuel BARTLETT | pending |
| Fused Heterobicyclic Antiviral AgentsC07D 285/36, A61P 31/20, A61K 31/554, A61K 45/06, C07D 417/06, C07D 417/12, C07D 513/04Filed as Enanta Pharmaceuticals, Inc.2025-03-10Sean RAFFERTY | pending |
| FUSED HETEROBICYCLIC ANTIVIRAL AGENTSFiled as ENANTA PHARMACEUTICALS, INC.2025-03-10SEAN RAFFERTY | pending |
| Anti-Inflammatory CompoundsFiled as Enanta Pharmaceuticals, Inc.2025-02-27Robert LEON | pending |
| Anti-Inflammatory CompoundsFiled as Enanta Pharmaceuticals, Inc.2025-02-27Sourav GHORAI | pending |
| PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORSFiled as Enanta Pharmaceuticals, Inc.2025-02-07Jiajun ZHANG | pending |
| PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORSC07D 519/00, A61K 31/4245, A61K 31/427, A61K 31/429, A61K 31/433, A61K 31/4365, A61K 31/437, A61K 31/4375, A61K 31/438, A61K 31/4439, A61K 31/444, A61K 31/454, A61K 31/46, A61K 31/4709, A61K 31/4745, A61K 31/497, A61K 31/498, A61K 31/4985, A61K 31/4995, A61K 31/501, A61K 31/5025, A61K 31/506, A61K 31/519, A61K 31/53, A61K 31/5377, A61K 31/538, A61K 31/5386, A61K 31/541, A61K 31/553, C07D 413/12, C07D 413/14, C07D 417/12, C07D 471/04, C07D 471/10, C07D 487/04, C07D 491/107, C07D 495/04, C07D 498/04, C07D 513/04Filed as Enanta Pharmaceuticals, Inc.2025-02-07Jiajun ZHANG | pending |
| Anti-Inflammatory CompoundsFiled as Enanta Pharmaceuticals, Inc.2024-12-17Sourav GHORAI | pending |
| CRYSTAL FORMS OF AN ANTI-RSV AGENTC07D 413/14Filed as Enanta Pharmaceuticals, Inc.2024-11-06Joseph HELBLE | pending |
| CRYSTAL FORMS OF AN ANTI-RSV AGENTFiled as ENANTA PHARMACEUTICALS, INC.2024-11-06JOSEPH HELBLE | pending |
| PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORSFiled as ENANTA PHARMACEUTICALS, INC.2024-10-25YAT SUN OR | pending |
| Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 InhibitorsC07D 495/04, A61P 1/16, A61P 11/00, A61K 31/519, A61K 31/7064, C07D 495/14, C07D 498/14, C07H 17/02Filed as ENANTA PHARMACEUTICALS, INC.2024-10-25Yat Sun OR | pending |
| 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOFFiled as ENANTA PHARMACEUTICALS, INC.2024-10-03YAOHUI NIE | pending |
| 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors And Methods Of Use ThereofA61K 31/426, A61P 11/00, A61K 31/196, A61K 31/343, A61K 31/404, A61K 31/415, A61K 31/4375, A61K 31/538Filed as ENANTA PHARMACEUTICALS, INC.2024-10-03Yaohui NIE | pending |
| Pharmaceutical Compounds and Compositions as C-Kit Kinase InhibitorsA61K 31/4245, A61K 31/53, C07D 413/14, C07D 487/04, A61P 1/16, A61P 11/06, A61P 17/00, A61P 3/10, A61P 1/00, A61P 11/00, A61P 29/00, A61K 31/429, A61K 31/433, A61K 31/437, A61K 31/4375, A61K 31/438, A61K 31/4439, A61K 31/444, A61K 31/4545, A61K 31/4709, A61K 31/496, A61K 31/497, A61K 31/498, A61K 31/4985, A61K 31/501, A61K 31/5025, A61K 31/506, A61K 31/519, A61K 31/5377, A61K 31/538, A61K 31/541, A61K 31/553, C07D 413/12, C07D 417/12, C07D 417/14, C07D 471/04, C07D 471/10, C07D 487/10, C07D 491/107, C07D 495/04, C07D 495/10, C07D 498/04, C07D 498/08, C07D 513/04, C07D 519/00Filed as Enanta Pharmaceuticals, Inc.2024-08-08Jiajun ZHANG | pending |
| PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORSFiled as ENANTA PHARMACEUTICALS, INC.2024-08-08JIAJUN ZHANG | pending |
| PROCESSES FOR THE PREPARATION OF OXADIAZOLYLAMINO BENZODIAZEPINE DERIVATIVESFiled as ENANTA PHARMACEUTICALS, INC.2024-08-08SCOTT CRAWFORD | pending |
| Processes For The Preparation Of Oxadiazolylamino Benzodiazepine DerivativesC07D 413/12, C07D 413/14, A61P 31/14, A61K 31/5513Filed as Enanta Pharmaceuticals, Inc.2024-08-08Scott CRAWFORD | pending |
| Pharmaceutical Compounds And Compositions As c-Kit Kinase InhibitorsC07D 471/04, A61K 31/437, A61K 31/444, A61K 31/497, A61K 31/501, A61K 31/506, C07D 519/00Filed as Enanta Pharmaceuticals, Inc.2024-07-24Yuk Ming SIU | pending |
| PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORSFiled as ENANTA PHARMACEUTICALS, INC.2024-07-24YUK MING SIU | pending |
| COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORSFiled as ENANTA PHARMACEUTICALS, INC.2024-07-12PEILIN XU | pending |
| Compounds and Compositions as C-Kit Kinase InhibitorsA61K 31/437, C07D 471/04, A61K 31/4985, C07D 519/00Filed as Enanta Pharmaceuticals, Inc.2024-07-12Peilin XU | pending |
| Pharmaceutical Compounds and Compositions as C-Kit Kinase InhibitorsFiled as Enanta Pharmaceuticals, Inc.2024-07-03Jiajun ZHANG | pending |
| Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use ThereofC07D 401/14, A61P 37/02, A61P 1/16, A61P 3/00, A61P 9/00, Y02A 50/30, A61P 13/12, A61P 25/00, A61P 29/00, A61K 31/4178, A61K 31/437, A61K 31/4439, A61K 31/4545, A61K 31/497, A61K 31/506, A61K 31/5377, C07D 403/12, C07D 403/14, C07D 405/14, C07D 413/14, C07D 417/14Filed as Enanta Pharmaceuticals, Inc.2024-05-10Guoqiang WANG | 12552777 |
| Hepatitis B Antiviral AgentsA61K 31/167, C07C 303/00, C07C 317/44, C07C2601/08, C07C2602/44, C07C2601/10, C07C2601/02, C07C2601/16, C07C2601/04, C07C2602/50, C07C2601/14, A61P 31/20, A61K 31/337, A61K 31/34, A61K 31/351, A61K 31/357, A61K 31/397, A61K 31/401, A61K 31/4015, A61K 31/415, A61K 31/4164, A61K 31/4192, A61K 31/421, A61K 31/426, A61K 31/4409, A61K 31/4439, A61K 31/47, A61K 31/513, A61K 31/7028, A61K 45/06, C07B2200/05, C07D 205/04, C07D 207/16, C07D 207/277, C07D 213/30, C07D 213/61, C07D 213/82, C07D 213/89, C07D 215/14, C07D 231/12, C07D 233/60, C07D 233/64, C07D 237/20, C07D 239/26, C07D 239/42, C07D 239/54, C07D 241/20, C07D 249/04, C07D 261/08, C07D 263/20, C07D 263/22, C07D 263/24, C07D 263/32, C07D 263/34, C07D 263/56, C07D 275/02, C07D 277/24, C07D 277/30, C07D 277/46, C07D 277/56, C07D 303/14, C07D 305/08, C07D 307/18, C07D 307/22, C07D 307/24, C07D 309/08, C07D 309/10, C07D 317/32, C07D 317/72, C07D 401/04, C07D 413/04, C07D 451/04, C07D 491/107, C07D 493/04Filed as Enanta Pharmaceuticals, Inc.2024-05-10Yao-Ling QIU | 12496282 |
| Antiviral Heterocyclic CompoundsC07D 491/048, C07D 491/052, C07D 471/04, C07D 491/044Filed as Enanta Pharmaceuticals, Inc.2024-04-26Adam SZYMANIAK | 12509470 |
| PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2Filed as Enanta Pharmaceuticals, Inc.2024-04-09Xuri GAO | pending |
| Antiviral Heterocyclic CompoundsA61K 45/06, C07D 491/048, A61P 31/14, A61P 31/16, A61K 31/4375, C07B 59/004, C07B2200/05, C07D 519/00Filed as Enanta Pharmaceuticals, Inc.2024-04-05Adam SZYMANIAK | pending |
| ANTIVIRAL HETEROCYCLIC COMPOUNDSFiled as ENANTA PHARMACEUTICALS, INC.2024-04-05ADAM SZYMANIAK | pending |
| Fused Heterobicyclic Antiviral AgentsFiled as Enanta Pharmaceuticals, Inc.2024-03-11Sean RAFFERTY | pending |
| Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use ThereofA61K 31/57, C07J 41/005, C07J 43/003, A61P 5/50, A61P 37/02, A61P 9/10, A61P 43/00, A61P 1/16, A61P 3/00, A61P 9/00, A61P 31/12, A61P 37/06, A61P 3/06, A61P 3/10, A61P 9/12, A61P 13/12, A61P 1/00, A61P 35/00, A61K 31/575, A61K 31/58, C07J 9/00, C07J 9/005, C07J 41/0055, C07J 41/0088, C07J 51/00Filed as Enanta Pharmaceuticals, Inc.2024-03-05Guoqiang WANG | 12753204 |
| Fused Heterotetracyclic Antiviral AgentsA61K 31/554, A61K 45/06, A61P 31/20, C07D 471/04, C07D 513/04Filed as Enanta Pharmaceuticals, Inc.2024-02-26Sean RAFFERTY | pending |
| FUSED HETEROTETRACYCLIC ANTIVIRAL AGENTSFiled as ENANTA PHARMACEUTICALS, INC.2024-02-26SEAN RAFFERTY | pending |
| Benzodiazepine Derivatives as RSV InhibitorsA61K 31/5513, C07D 243/16, C07D 413/12, C07D 513/04, A61P 31/12, A61P 11/00, A61P 31/16, A61K 31/56, A61K 31/58, A61K 45/06, A61K2300/00, C07D 243/24, C07D 413/14, C07D 417/12, C07D 417/14, C07D 471/04, C07D 471/08, C07D 487/04, C07D 491/048, C07D 495/04, C07D 498/08Filed as Enanta Pharmaceuticals, Inc.2024-02-22Brian C. SHOOK | 12297209 |
| Fused Heterobicyclic Antiviral AgentsC07D 285/36, C07D 417/04, C07D 417/12, C07D 513/04Filed as Enanta Pharmaceuticals, Inc.2024-02-21Samuel BARTLETT | pending |
| BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORSA61K 45/06, C07D 413/14, A61P 31/12, A61P 31/14, A61P 31/16, A61K 31/5513, C07D 417/14, A61K2300/00Filed as Enanta Pharmaceuticals, Inc.2024-01-24Kaicheng Zhu | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on ENTA
Company overviewEverything on ENTA in one place, with the price.SEC filingsWhat ENTA's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat ENTA's own officers and directors buy and sell.Who owns itEvery manager reporting a position in ENTA.Funds holding itWhich funds and ETFs hold ENTA, and how big a bet.